Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer

Investigational New Drugs
Makoto NishioTomohide Tamura

Abstract

Onartuzumab is a monovalent, humanized, monoclonal antibody that showed significant survival benefits in combination with erlotinib in MET-positive non-small-cell lung cancer (NSCLC) in pre-specified subgroup analyses of a randomized phase II study. We conducted a two-stage, open-label, multicenter, phase I study of onartuzumab in Japanese patients. Stage 1 investigated the safety, tolerability, pharmacokinetics (PK), and recommended dose of onartuzumab in patients with solid tumors, and Stage 2 determined the safety, tolerability, and PK of onartuzumab plus erlotinib in patients with MET-positive NSCLC. Nine patients received onartuzumab monotherapy (4, 15, or 30 mg/kg on Day 1 of each 21-day cycle) in Stage 1, and six patients received onartuzumab (15 mg/kg) plus erlotinib (150 mg/day) in Stage 2. There were no dose-limiting toxicities in either stage. Serious adverse events (AEs) occurred in one patient in Stage 1 (convulsion), and two patients in Stage 2 (once case each of diarrhea, vomiting, and pulmonary embolism), but there were no grade 4 AEs or AEs leading to death. Onartuzumab PKs were linear in the dose range of 4 to 30 mg/kg, and were not affected by co-administration with erlotinib. PK parameters of onartuzumab wer...Continue Reading

References

Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M HidalgoE K Rowinsky
Dec 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·James BeanWilliam Pao
Dec 6, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Kaoru KubotaNagahiro Saijo
Jan 13, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rafal DziadziuszkoFred R Hirsch
Mar 29, 2013·Molecular Cancer Therapeutics·Elicia PenuelPriti S Hegde
Jul 25, 2013·Proceedings of the National Academy of Sciences of the United States of America·Mark MerchantDaniel G Yansura
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David R SpigelAmy C Peterson
Oct 10, 2013·The Journal of Pathology·Hartmut KoeppenRobert L Yauch
Feb 5, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ravi SalgiaRebecca A Moss

❮ Previous
Next ❯

Citations

Sep 13, 2019·Critical Reviews in Clinical Laboratory Sciences·Fatemeh MoosaviOmidreza Firuzi
May 17, 2019·Expert Opinion on Emerging Drugs·Umberto Malapelle, Antonio Rossi
Jun 10, 2020·Nature Reviews. Clinical Oncology·Robin GuoAlexander Drilon
Oct 28, 2015·Diseases·Joycelyn J X LeeSu Pin Choo
Mar 17, 2018·Molecular Cancer Therapeutics·Sofie Ellebaek PollmannThomas Tuxen Poulsen
Apr 5, 2017·Molecular Cancer Therapeutics·Ravi Salgia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.